WO2010118367A3 - Pyrimidines antivirales - Google Patents

Pyrimidines antivirales Download PDF

Info

Publication number
WO2010118367A3
WO2010118367A3 PCT/US2010/030598 US2010030598W WO2010118367A3 WO 2010118367 A3 WO2010118367 A3 WO 2010118367A3 US 2010030598 W US2010030598 W US 2010030598W WO 2010118367 A3 WO2010118367 A3 WO 2010118367A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
infection
pyrimidines
pyrazolopyrimtdines
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/030598
Other languages
English (en)
Other versions
WO2010118367A2 (fr
Inventor
Amy Qi Han
Eric Wang
Carla Gauss
Walter Xie
Glen Coburn
Jean-Marc Demuys
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progenics Pharmaceuticals Inc
Original Assignee
Progenics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharmaceuticals Inc filed Critical Progenics Pharmaceuticals Inc
Publication of WO2010118367A2 publication Critical patent/WO2010118367A2/fr
Publication of WO2010118367A3 publication Critical patent/WO2010118367A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne de nouveaux composés comprenant des pyrimidines, des pyrazolopyrimidines, et des imidazolopyrimidines substituées, leurs synthèses, et des compositions les comprenant, y compris des compositions pharmaceutiques, comprenant les nouvelles pyrimidines, pyrazolopyrimidines, imidazolpyrimidines et des composés analogues. De tels composés fonctionnent en inhibant l'entrée des virus de la famille des Flaviviridae, y compris le virus de l'hépatite C (VHC), à l'intérieur des cellules qui sont susceptibles d'être infectées par les virus. Ces composés sont utiles dans le traitement, la thérapie et/ou la prophylaxie de maladies virales et d'infections, y compris l'infection par le VHC.
PCT/US2010/030598 2009-04-10 2010-04-09 Pyrimidines antivirales Ceased WO2010118367A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16832309P 2009-04-10 2009-04-10
US61/168,323 2009-04-10

Publications (2)

Publication Number Publication Date
WO2010118367A2 WO2010118367A2 (fr) 2010-10-14
WO2010118367A3 true WO2010118367A3 (fr) 2011-03-10

Family

ID=42936895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/030598 Ceased WO2010118367A2 (fr) 2009-04-10 2010-04-09 Pyrimidines antivirales

Country Status (1)

Country Link
WO (1) WO2010118367A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US9718825B2 (en) 2013-03-13 2017-08-01 Sanofi N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
US11730736B2 (en) 2017-11-06 2023-08-22 Rapt Therapeutics, Inc. Anticancer agents

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101763656B1 (ko) 2009-06-29 2017-08-01 인사이트 홀딩스 코포레이션 Ｐｉ3ｋ 저해물질로서의 피리미디논
AU2010306803A1 (en) 2009-10-14 2012-05-03 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8445490B2 (en) 2009-10-14 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2558463A1 (fr) 2010-04-14 2013-02-20 Incyte Corporation Dérivés condensés en tant qu'inhibiteurs de i3
WO2011139513A1 (fr) 2010-05-04 2011-11-10 Bristol-Myers Squibb Company Composés destinés au traitement de l'hépatite c
WO2011163195A1 (fr) 2010-06-21 2011-12-29 Incyte Corporation Dérivés condensés de pyrrole en tant qu'inhibiteurs de pi3k
US8765944B2 (en) 2010-08-19 2014-07-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP3660016A1 (fr) 2010-12-20 2020-06-03 Incyte Holdings Corporation N-(1-(phényl substitué)éthyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (fr) 2011-03-25 2012-10-04 Incyte Corporation Dérivés de pyrimidine-4,6-diamine en tant qu'inhibiteurs de pi3k
US8933066B2 (en) 2011-04-14 2015-01-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
AP2013007253A0 (en) 2011-04-21 2013-11-30 Origenis Gmbh Pyrazolo [4,3-D] pyrimidines useful as kinase inhibitors
PT3513793T (pt) 2011-09-02 2021-05-10 Incyte Holdings Corp Heterociclilaminas como inibidores de pi3k
EP2758402B9 (fr) 2011-09-22 2016-09-14 Pfizer Inc Dérivés de pyrrolopyrimidine et de purine
US8629150B2 (en) 2011-09-28 2014-01-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8697706B2 (en) 2011-10-14 2014-04-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8916702B2 (en) 2012-02-06 2014-12-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CN104540830A (zh) * 2012-06-07 2015-04-22 霍夫曼-拉罗奇有限公司 端锚聚合酶的吡唑并嘧啶酮和吡唑并吡啶酮抑制剂
CN102827085A (zh) * 2012-09-17 2012-12-19 符爱清 2,4,5-三氯嘧啶化合物的制备方法
CN102952086B (zh) * 2012-09-28 2013-08-28 天津科创医药中间体技术生产力促进有限公司 一种2-吗啉基取代嘧啶类化合物的制备方法
CN102887860B (zh) * 2012-09-29 2015-07-01 上海泰坦科技有限公司 4-氯-6-三氟甲基嘧啶类化合物的制备方法
US9422311B2 (en) 2012-10-18 2016-08-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2014060112A1 (fr) * 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines utiles en tant qu'inhibiteurs de kinases
AU2013343105B2 (en) 2012-11-08 2016-04-14 Pfizer Inc. Heteroaromatic compounds as dopamine D1 ligands
JP6298830B2 (ja) * 2012-12-20 2018-03-20 ユーシービー バイオファルマ エスピーアールエル 治療用に活性なピラゾロ−ピリミジン誘導体
JP2016507560A (ja) 2013-02-07 2016-03-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｃｖエントリー阻害剤としての大環状化合物
WO2014123892A1 (fr) 2013-02-07 2014-08-14 Bristol-Myers Squibb Company Molécules macrocycliques utilisées en tant qu'inhibiteurs de la pénétration du vhc
EA027935B1 (ru) 2013-03-07 2017-09-29 Ф. Хоффманн-Ля Рош Аг Новые производные пиразола
CN105143233A (zh) 2013-03-07 2015-12-09 百时美施贵宝公司 用于治疗丙型肝炎的化合物
CN105209466B (zh) 2013-05-02 2018-05-18 豪夫迈·罗氏有限公司 作为cb2受体激动剂的嘌呤衍生物
HUE035333T2 (en) 2013-05-02 2018-05-02 Hoffmann La Roche Pyrrolo [2,3-d] pyrimidine derivatives as CB2 receptor agonists
US9879014B2 (en) * 2013-07-12 2018-01-30 Kyoto University Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease
WO2015057945A1 (fr) 2013-10-18 2015-04-23 Indiana University Research And Technology Corporation Effecteurs d'assemblage de virus de l'hépatite b
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
ES2919024T3 (es) 2014-02-11 2022-07-21 Mitokinin Inc Composiciones y procedimientos que utilizan las mismas para el tratamiento de enfermedades neurodegenerativas y mitocondriales
WO2015162515A1 (fr) 2014-04-25 2015-10-29 Pfizer Inc. Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1
EP3134405B1 (fr) 2014-04-25 2019-08-28 Pfizer Inc Composes hetero-aromatiques et leur utilisation comme ligands d1 de la dopamine
WO2015191677A1 (fr) 2014-06-11 2015-12-17 Incyte Corporation Dérivés d'hétéroarylaminoalkylphényle bicycliques à titre d'inhibiteurs de pi3k
CA2973949C (fr) 2015-01-16 2023-07-11 The General Hospital Corporation Composes pour ameliorer l'epissage de l'arnm
SG10201907576SA (en) 2015-02-27 2019-09-27 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
CA2982811A1 (fr) 2015-04-17 2016-10-20 Indiana University Research And Technology Corporation Effecteurs d'assemblage de virus de l'hepatite b
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018049214A1 (fr) 2016-09-09 2018-03-15 Incyte Corporation Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
CN115819417A (zh) 2016-09-09 2023-03-21 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
RU2019112740A (ru) * 2016-09-30 2020-11-02 АСАНА БАЙОСАЙЕНСИЗ, ЭлЭлСи P2x3 и/или p2x2/3 соединения и способы
WO2018152220A1 (fr) 2017-02-15 2018-08-23 Incyte Corporation Composés de pyrazolopyridine et leurs utilisations
WO2018151326A1 (fr) 2017-02-20 2018-08-23 国立大学法人京都大学 Composition pharmaceutique et méthode de traitement pour une maladie génétique associée à des anomalies d'épissage
CN107383014B (zh) * 2017-06-21 2019-04-30 南方医科大学 一种1H-吡唑并[3,4-d]嘧啶类化合物及其制备方法和应用
AU2018290225A1 (en) 2017-06-21 2020-01-23 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
EP3755703B1 (fr) 2018-02-20 2022-05-04 Incyte Corporation Dérivés n-(phényl)-2-(phényl)pyrimidine-4-carboxamide et composés similaires en tant qu'inhibiteurs de hpk1 pour le traitemant du cancer
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
SG11202011680YA (en) 2018-06-01 2020-12-30 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
WO2020068729A1 (fr) 2018-09-25 2020-04-02 Incyte Corporation Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr
US12054488B2 (en) 2018-09-27 2024-08-06 Suzhou Raymon Pharmaceuticals Company, Ltd. Pyrazolopyrimidine compound and preparation method therefor and use thereof in preparation of anti-cancer drug
CN110698432B (zh) * 2018-11-07 2023-02-03 中国医学科学院医药生物技术研究所 苯甲基哌嗪类化合物及其制备方法和在抗病毒中的应用
CN111170992B (zh) * 2018-11-12 2021-05-14 新发药业有限公司 一种5,6-二氢吡啶-2(1h)-酮衍生物的制备方法
US20220024891A1 (en) * 2018-12-04 2022-01-27 The Board Of Regents Of The University Of Texas System Therapeutics targeting mutant adenomatous polyposis coli (apc) for the treatment of cancer
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (fr) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Composés de pyrrolo[2,3-d] pyrimidine pour le traitement de la dysautonomie familiale
AU2020258017B2 (en) * 2019-04-18 2025-05-29 Université de Liège New pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling
BR112022002059A2 (pt) 2019-08-06 2022-06-07 Incyte Corp Formas sólidas de um inibidor de hpk1
CN110437253A (zh) * 2019-08-06 2019-11-12 复旦大学 含联苯结构的二芳基嘧啶并环化合物及其制备方法和用途
EP4028133A1 (fr) 2019-09-13 2022-07-20 The United States of America, as represented by The Secretary, Department of Health and Human Services Inhibiteurs du récepteur de la tyrosine kinase pour le traitement de maladie ou de trouble sensible à la modulation de la protéine kinase
EP3800188A1 (fr) 2019-10-02 2021-04-07 Bayer AG Pyrazolopyrimidines substituées en tant qu'inhibiteurs d'irak4
US11939307B2 (en) 2019-11-29 2024-03-26 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Phenylmethyl-piperazine derivatives and antiviral uses thereof
US20230121698A1 (en) * 2019-12-23 2023-04-20 Sanford Burnham Prebys Medical Discovery Institute Ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) modulators and uses thereof
US12577211B2 (en) 2020-06-29 2026-03-17 Bacainn Biotherapeutics, Ltd. Probenecid compounds for the treatment of inflammasome-mediated lung disease
CN111732575B (zh) * 2020-08-03 2020-12-11 北京鑫开元医药科技有限公司 一种n-(3-(嘧啶-2-基)苯基)苯磺酰胺类衍生物、药物组合物、制备方法及应用
WO2022123310A1 (fr) 2020-12-11 2022-06-16 Ildong Pharmaceutical Co., Ltd. Nouveaux composés en tant qu'inhibiteurs doubles du récepteur des androgènes et de la phosphodiestérase
CN113292452B (zh) * 2021-06-01 2023-03-24 山东京博生物科技有限公司 一种氰基乙酰胺的合成方法
CN113979945A (zh) * 2021-11-15 2022-01-28 湖北理工学院 一种制备3-氨基吡唑-4-甲酰胺半硫酸盐的新方法
US20240247001A1 (en) 2022-12-16 2024-07-25 Astrazeneca Ab 2,6,9-trisubstituted purines
WO2024168104A2 (fr) * 2023-02-09 2024-08-15 Caraway Therapeutics, Inc. Modulateurs de trpml, leurs compositions et procédés d'utilisation
EP4661864A2 (fr) * 2023-02-09 2025-12-17 Caraway Therapeutics, Inc. Modulateurs de trpml, leurs compositions et procédés d'utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478830A (en) * 1992-05-29 1995-12-26 The Du Pont Merck Pharmaceutical Company Fused-ring heterocycles for the treatment of atherosclerosis
JP2004506737A (ja) * 2000-08-18 2004-03-04 アグーロン　ファーマシューティカルズ，インコーポレイテッド ピラゾール化合物、薬剤組成物、およびｅｒａｂまたはｈａｄｈ２活性の調節または阻害方法
WO2005121107A1 (fr) * 2004-06-09 2005-12-22 F. Hoffmann-La Roche Ag Pyrazolopyrimidines
WO2006132460A1 (fr) * 2005-06-10 2006-12-14 Dong-A Pharmaceutical.Co., Ltd. Agent pour la prevention et le traitement des maladies du foie contenant un derive de la pyrazolopyrimidine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478830A (en) * 1992-05-29 1995-12-26 The Du Pont Merck Pharmaceutical Company Fused-ring heterocycles for the treatment of atherosclerosis
JP2004506737A (ja) * 2000-08-18 2004-03-04 アグーロン　ファーマシューティカルズ，インコーポレイテッド ピラゾール化合物、薬剤組成物、およびｅｒａｂまたはｈａｄｈ２活性の調節または阻害方法
WO2005121107A1 (fr) * 2004-06-09 2005-12-22 F. Hoffmann-La Roche Ag Pyrazolopyrimidines
WO2006132460A1 (fr) * 2005-06-10 2006-12-14 Dong-A Pharmaceutical.Co., Ltd. Agent pour la prevention et le traitement des maladies du foie contenant un derive de la pyrazolopyrimidine

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9637492B2 (en) 2008-03-14 2017-05-02 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US9828378B2 (en) 2008-07-08 2017-11-28 Intellikine Llc Kinase inhibitors and methods of use
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9718825B2 (en) 2013-03-13 2017-08-01 Sanofi N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
US11730736B2 (en) 2017-11-06 2023-08-22 Rapt Therapeutics, Inc. Anticancer agents

Also Published As

Publication number Publication date
WO2010118367A2 (fr) 2010-10-14

Similar Documents

Publication Publication Date Title
WO2010118367A3 (fr) Pyrimidines antivirales
WO2009091388A3 (fr) Triazines et composés associés présentant une activité antivirale, compositions et procédés associés
WO2011041713A3 (fr) Agents anti-viraux à base de pipérazinyle
MX2010009563A (es) Compuestos quimicos con accion antiviral contra virus de dengue y otros flavivirus.
EP2853531A3 (fr) Composés antiviraux
PH12012502343A1 (en) Antiviral drugs for treatment or prevention of dengue infection
EA201390538A1 (ru) Противовирусные соединения
EA201000556A1 (ru) Спиропирролидины и их применение для борьбы с инфицированием посредством hcv (вирус гепатита с) и вич (вирус иммунодефицита человека)
WO2010081082A3 (fr) Dérivés de phosphoramidate de composés guanosine nucléoside pour le traitement d'infections virales
IL195025A (en) History of compressed indolubenzazepine with cyclopropyl and pharmaceuticals containing them as an anti-hcv drug
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
MY152971A (en) Hepatitis c virus inhibitors
WO2012092484A3 (fr) Nucléosides puriques substitués, dérivés phosphoramidate et phosphorodiamidate pour le traitement d'infections virales
WO2008021936A3 (fr) Inhibiteurs du virus de l'hépatite c
ATE475660T1 (de) Antivirale verbindungen
WO2011106992A8 (fr) Inhibiteurs de polymérase du virus de l'hépatite c ns5b
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
WO2010055164A3 (fr) Nouveaux inhibiteurs de la réplication de flavivirus
CA2862755A1 (fr) Composes antiviraux avec une fraction dibenzooxaheterocycle
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
WO2009094190A3 (fr) Méthodes de traitement d’infections virales
AU2012332832A8 (en) Compositions useful for the treatment of viral diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10762525

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10762525

Country of ref document: EP

Kind code of ref document: A2